Marijuana

This presentation describes the nature of the merge of the e-cigarette and cannabis industries. Quality assurance issues as a result of the absence of regulation and oversight is described. Cases of self-reported adverse events and the challenges of cannabis product analysis are also discussed.

This webinar was hosted by the NIJ Forensic Technology Center of Excellence on June 29, 2023. 

With the passage of the 2018 Agricultural Improvement Act (Farm Bill), forensic laboratories have been tasked with differentiating seized cannabis samples as either hemp or marijuana. The new legislation declassified hemp as a Schedule 1 drug substance and defined it as cannabis containing 0.3 % or less of decarboxylated-Δ9-THC (total Δ9-THC). The National Institute of Standards and Technology (NIST) has been working to help forensic laboratories with these challenging measurements through the development of extraction protocols and analytical methods.

The reauthorization of hemp due to the Agriculture Improvement Act of 2018 (Farm Bill) has caused a proliferation of products that contain cannabidiol (CBD). While CBD is considered ‘legal’ under the Farm-Bill, there are concerns that the labeling of CBD products is inaccurate, and that the products may contain other cannabinoids, including Δ9-tetrahydrocannabinol (THC), the main psychoactive compound in marijuana. Other concerns include the potential for conversion of CBD to other cannabinoids during analysis of biological matrices and in acidic foods and beverages.

As evident by the Cannabinoid Connundrums webinar series, the rapidly changing world of cannabinoids offers many conundrums. To tackle some of these questions, Dr. Ruth Winecker led a panel discussion with Dr. Ed Cone, Dr. Nathalie Desrosiers, Mr. Justin Poklis, and Mr. Nelson Santos. This diverse slate of thought leaders includes experts in analytical chemistry, forensic toxicology, clinical research, and drug chemistry. This webinar was hosted by the NIJ Forensic Technology Center of Excellence on August 3, 2023. 

Controlled drug administration studies are valuable tools for acquiring a detailed understanding of the pharmacodynamic and pharmacokinetic profiles of cannabinoids. ∆9-tetrahydrocannabinoid (THC) is the primary psychoactive cannabinoid in cannabis with the potential to negatively impact cognitive and psychomotor performance and workplace safety. These studies establish behavioral and subjective effect profiles while simultaneously collecting pharmacokinetics data.

THC isomers, also known as THC analogs or semi-synthetic cannabinoids, are structurally related to Δ9-tetrahydrocannabinol (Δ9-THC) and have similar toxicity and impairing effects. A recent study indicated that Δ8-THC use was around 27% of marijuana use, based on detection and ratios of cannabinoid metabolites in workplace drug testing. Other analogs of interest include hexahydrocannabinol (HHC) and THC-O. THC isomers are generally perceived as legal and are also seen in states with legal marijuana.

This webinar will focus on the journey through medical marijuana and the decriminalization of hemp with legalization on the horizon in the state of Ohio. We will also focus on the impact that legalization has made in the state of Colorado over the past 10 years. The journey between these two states will demonstrate the challenges and needs for a shift in the analytical approach.

This webinar was hosted by the NIJ Forensic Technology Center of Excellence on April 5, 2022, as part of the ASCLD Train the Director Webinar Series.